Skip to main content

Sero-epidemiological study in prediction of the risk groups for measles outbreaks in Vojvodina, Serbia.

Serological survey provides insight grouped age gap measles-specific immunity and the expected prevalence of a certain age. The purpose Ovine Clia Kits of this study was to describe the sero-epidemiology of measles in Vojvodina before the outbreak in 2017/18 and to discuss preventive measures for the future potential epidemics.

A seroprevalence study was conducted from April 2015 to June 2017 by the 3199 serum samples leftovers , The study was conducted prior to the last measles outbreak in Vojvodina which occurred between 12 November 2017 and June 30, 2018. Measles-specific IgG antibodies were determined by using indirect chemiluminescent immunoassay (CLIA) registered participants .Median age was 20 years (IQR 11- 37). Overall, 86.9% of serum samples were seropositive. The highest proportion of measles seronegativity observed in children aged 12-23 months and in adults aged 20-39 years (56.1% and 18.5%, respectively). 

The prevalence of measles seronegativity above the WHO target level of susceptibility was observed in the following age groups: 2, 7, 13, 15, and among all adults aged between 20 and 49 years old. Of the total cases of measles outbreaks (177), there were 91 (51.4%) participants aged 20-39 years. A significant positive correlation was observed between measles seronegativity and the number of reported measles cases aged ≥ 12 months (r = 0.4675, p = 0.0213) .I

n order to prevent new outbreaks and achieve the elimination of measles in Vojvodina, the second measles vaccination coverage -gondong-rubella (MMR1 and MMR2) vaccine needs upgraded and maintained. education campaign to increase acceptance and timely vaccination with measles vaccine among doctors and the general public is very important. Our results suggest the possibility of gaps in the protection against measles in adults born during the execution of one dose of measles vaccine and supplemental immunization activities to prioritize targeting adults in Vojvodina, Serbia.

Point-of-care (POC) hemoglobin testing has the potential to Porcine Clia Kits revolutionize the strategy of massive transfusion. No previous studies have compared the POC and central laboratory testing of hemoglobin in patients undergoing major transfusions.We retrospectively compared the results of hemoglobin test point-of-care we (EPOC®) core laboratory to our complete blood count (CBC) test hemoglobin (Sysmex XE -5000 ™) in patients undergoing massive transfusion protocol (MTP) for bleeding. One hundred seventy paired samples from 90 patients for whom the activated MTP collected at a single tertiary care hospital between 10/2011 and 10/2017. 
Sero-epidemiological study in prediction of the risk groups for measles outbreaks in Vojvodina, Serbia.

Patients have both a EPOC® and CBC hemoglobin done within 30 minutes of each other during the MTP. We assess the accuracy EPOC® hemoglobin testing using two variables: the exchange and clinically significant differences from the CBC. The criteria Clinical Laboratory Improvement Amendments (CLIA) proficiency test for measurement defined exchange. Clinically significant difference between the test is defined by an expert panel.
Labels:

Comments

Post a Comment

Popular posts from this blog

Advances in hemoglobin A1c point of care technology.

Measurement of hemoglobin A1c (A1C) has long been accepted as the best indicator of glucose control over time. A1C tests for the technology used by both differences in costs (high pressure liquid chromatography) or structure (boronate affinity or immunoassay combined with general chemistry). This technology is commonly used in expensive laboratory instruments. More recently, technology A1C has been put into place care (POC) devices, allowing for the availability  Simian Clia Kits of measurement of A1C, greatly facilitate diabetes care in both specialist and general practice.  A1C POC tests must have acceptable performance, standardization of national reference, the National Glycohemoglobin Standardization Program (NGSP) certification, simple operation without the need for expensive instrumentation, and the Clinical Laboratory Improvement Amendments (CLIA) waiver. CLIA-waived POC technologies including Bio-Rad MicroMat II (distributed by a Cholestech GDX) and Axis-Shield Afi...
Post a Comment
Read more

Infrastructure for Personalized Medicine at Partners HealthCare.

Partners HealthCare Personalized Medicine (PPM) is central in partner systems HealthCare (founded by Massachusetts General Hospital and Brigham and Women's Hospital) whose mission is to utilize genetics and genomics to improve patient care in a cost effective manner.  PPM consists of five interrelated  Equine Clia Kits components: (1) Laboratory of Molecular Medicine (LMM), CLIA laboratories perform genetic testing for patients around the world; (2) Translational Genomics Core (TGC), a core lab provides a platform for researchers Partners genome; (3) Options Biobank, a Biobank samples (DNA, plasma and serum) for 50,000 patients agree Partners; (4) Biobank Portal, IT infrastructure and the viewer to unify genotype, sample, phenotype (validated diagnosis, radiology, and clinical chemistry) of electronic medical records researchers Partners. These components are held together by (5) common IT system that brings researchers, clinicians, and patients together for optimal research...
Post a Comment
Read more

Assessment of Etest as an alternative to agar dilution for antimicrobial susceptibility testing of Neisseria gonorrhoeae.

We studied whether the Etest can be used as an alternative to dilution in order to determine the antimicrobial susceptibility of ceftriaxone, cefixime and cefpodoxime in the supervision of Neisseria gonorrhoeae. One hundred fifteen clinical and laboratory  Caprine Clia Kits isolates of N. gonorrhoeae were tested following the Clinical Laboratory Improvement Amendments (CLIA) approved CLSI standard dilution methods to ensure and, separately, with Etest according to the manufacturer's recommendations. The MIC is determined and compared.  The resulting mutant laboratory used to simulate ten specimens substantially nonsusceptible. The Etest and agar dilution method were well correlated. The resulting statistical test regression R2 values ​​of 88%, 82%, and 85% and the Pearson correlation coefficient of 92%, 91%, and 92% for ceftriaxone, cefixime and cefpodoxime, respectively. When pairwise comparisons were made, two tests were 88.7%, 80%, and 87% within 1 log2 dilution of each oth...
Post a Comment
Read more